- Conditions
- Kidney Disease, Chronic
- Interventions
- BI 690517, Placebo matching BI 690517, Empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 45
- States / cities
- Huntsville, Alabama • Surprise, Arizona • Beverly Hills, California + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Failure
- Interventions
- vicadrostat, empagliflozin, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 94
- States / cities
- Mobile, Alabama • Chula Vista, California • Orange, California + 81 more
- Conditions
- Liver Diseases, Healthy
- Interventions
- BI 690517
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Orlando, Florida
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Interventions
- Vicadrostat, Empagliflozin, Placebo matching Vicadrostat
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 210
- States / cities
- Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 173 more
- Conditions
- Heart Failure
- Interventions
- vicadrostat, empagliflozin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 91
- States / cities
- Beverly Hills, California • Covina, California • Encinitas, California + 77 more
- Conditions
- Kidney Disease, Chronic
- Interventions
- BI 690517, Placebo to BI 690517, Empagliflozin, Placebo to empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 714 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 41
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more